107432-15-5Relevant academic research and scientific papers
Therapeutic uses of tri-aryl acid derivatives
-
Page/Page column 150-151, (2010/10/20)
The use of triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.
QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4
-
, (2008/06/13)
This invention relates to certain quinolinyl-benzopyran compounds and their use as valuable pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists and/or mediator release inhibitors possessing anti-inflammatory and anti-allergic properties.
QUINOLINYL-BENZOHETEROBICYCLIC DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4
-
, (2008/06/13)
This invention relates to certain quinolinyl-benzoheterobicyclic compounds and their use as valuable pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists and/or as mediator release inhibitors useful as anti-inflamm
Quinoline derivatives and use thereof as antagonists of leukotriene D4
-
, (2008/06/13)
This invention relates to quinolinyl compounds of the general formula: STR1 and the use of these compounds as pharmacological agents which are lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties
QUINOLINYL-CHROMONE DERIVATIVES AND USE FOR TREATMENT OF HYPERSENSITIVE AILMENTS
-
, (2008/06/13)
This invention relates to certain quinolinyl-chromone compounds and their use as valuable pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties.
Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships
Youssefyeh,Magnien,Lee,Chan,Lin,Galemmo Jr.,Johnson Jr.,Tan,Campbell,Huang,Nuss,Carnathan,Sutherland,Van Inwegen
, p. 1186 - 1194 (2007/10/02)
This series of reports describes the development of orally active, highly potent, specific antagonists of the peptidoleukotrienes containing a (2-quinolinylmethoxy)phenyl moiety. Described in this first report are the structure-activity relationships that led to more than a 20-fold improvement of the potency and selectivity of the initial chemical lead (RG 5901). From this series of compounds, RG 7152 (16) was identified and selected for further evaluation in the clinic as an antiasthmatic agent. Compound 16 competitively inhibits [3H]LTD4 binding to membranes from guinea pigs lung (K(i) = 38 ± 6 nM) and the spasmogenic activity of LTC4, LTD4, and LTE4 in parenchymal lung strips from guinea pigs. Unlike the original lead (RG 5901), compound 16 does not inhibit 5-lipoxygenase from guinea pig PMNs. Following oral administration to guinea pigs, 16 blocks LTD4-induced dermal permeability (ED50 = 6.9 mg/kg), LTD4-induced bronchoconstriction (ED50 = 1.1 mg/kg), antigen-induced bronchoconstriction (ED50 = 2.5 mg/kg), and anaphylactic-induced mortality (ED50 = 16 mg/kg). These studies on structure-activity relationships indicate that there is a requirement for an acidic function and the presence of the (2-quinolinylmethoxy)phenyl moiety in a specific geometric arrangement.
QUINOLINYL ETHER OR THIOETHER TETRAZOLES AS AGENTS FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS
-
, (2008/06/13)
This invention relates to certain quinolyl ether and thioether tetrazoles and their use as valuable pharmaceutical agents for the treatment of hypersensitive ailments, particularly as lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-
3(2-quinolinylalkoxy)phenols
-
, (2008/06/13)
There are disclosed compounds of the formula STR1 wherein Z is CR or N, when n=1; or Z is O, S, or NR, when n=0; n is 0 or 1; p is 1-10; R1 is hydrogen, loweralkyl, loweralkoxy or halo; R2 is hydrogen, loweralkyl, loweralkoxy or halo
